Who
Patrick R. O'Neil
EVP CLO & General Counsel
Company insider
Files Form 4 as: EVP CLO & General Counsel, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 524
- Buys
- 0
- Sells
- 93
- Bought
- $0
- Sold
- $38.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2013
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $3,23263 at $51.31 | filing |
| 31 Aug 2026filed 2 Sep 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $3,23363 at $51.31 | filing |
| 26 Jun 2026filed 30 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $246K3,069 at $80.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $246K3,069 at $80.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $764K10,148 at $75.25 | filing |
| 9 Mar 2026filed 11 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $764K10,148 at $75.25 | filing |
| 27 Feb 2026filed 3 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $18K376 at $48.87 | filing |
| 27 Feb 2026filed 3 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $18K376 at $48.87 | filing |
| 30 Jan 2026filed 2 Feb 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $516K6,179 at $83.53 | filing |
| 30 Jan 2026filed 2 Feb 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $516K6,179 at $83.53 | filing |
| 29 Jan 2026filed 2 Feb 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —11,991 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —11,991 at $0.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $697K9,191 at $75.84 | filing |
| 16 Jan 2026filed 20 Jan 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $697K9,191 at $75.84 | filing |
| 15 Jan 2026filed 20 Jan 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —21,473 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,473 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,675 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,473 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Patrick R. O'Neil; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.